MapLight Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Selling, General & Admin	37.8	30.73	14.42
Research & Development	172.25	138.35	68.52
Total Operating Expenses	210.04	169.08	82.95
Operating Income	-210.04	-169.08	-82.95
Interest Income	7.18	5.52	3.52
Other Non-Operating Income (Expense)	3.38	2.41	1.85
Total Non-Operating Income (Expense)	10.56	7.93	5.37
Pretax Income	-199.48	-161.15	-77.58
Net Income	-199.48	-161.15	-77.58
Net Income to Common	-199.48	-161.15	-77.58
Shares Outstanding (Basic)	20	9	1
Shares Outstanding (Diluted)	20	9	1
Shares Change (YoY)	2582.10%	1079.16%	-
EPS (Basic)	-80.12	-18.56	-105.38
EPS (Diluted)	-80.12	-18.56	-105.38
Shares Outstanding	2.73	44.02	0.76
Free Cash Flow	-	-138.61	-79.59
Free Cash Flow Per Share	-	-15.97	-108.11
EBITDA	-210.04	-168.51	-82.25
EBIT	-210.04	-169.08	-82.95

SEC Filings: 10-K · 10-Q